News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 4, 2020

In an Instant: The Changing Face of Psychiatry

Author(s)P Priyanka, MD

FaceTime, Skype, and other video chat functions are the new normal in the COVID-19 era, and allow this community psychiatrist serve the underserved.

Medical Director for California-based Community Psychiatry, Dr Priyanka shares her experience with telepsychiatry and discusses the transformation of telemedicine before, during, and (hopefully) after COVID-19. Community Psychiatry is an outpatient psychiatric care company with over 120 clinicians in over 40 locations across California.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

The Positive Impact of Prescription Digital Therapeutics: Insights From Patricia Ares-Romero, MD

ByPatricia Ares-Romero, MD, FASAM

November 21st 2025

digital therapeutic

Prescription Digital Therapeutics: Transforming Health Care Delivery

November 21st 2025

AI notes

Using AI to Write Psychiatric Progress Notes

ByDinah Miller, MD

November 18th 2025

porous

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 29th 2025

social determinants of health and mental health

Social Determinants of Health and Mental Health: Concepts and Practice of Growing Relevance

ByRenato D. Alarcón, MD, MPH,Dilip V. Jeste, MD

October 16th 2025

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

November in Review: Updates on the Psychiatric Treatment Pipeline

Looking Back: Key Insights from November 2025

New Drug Application Submitted for Centanafidine for Treatment of ADHD

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

© 2025 MJH Life Sciences^®

All rights reserved.